New drug toxicities in the onco-nephrology world

Kidney Int. 2015 May;87(5):909-17. doi: 10.1038/ki.2015.30. Epub 2015 Feb 11.


New anticancer medications are rapidly entering the clinical arena offering patients with previously resistant cancers the promise of more effective therapies capable of extending their lives. However, adverse renal consequences develop in treated patients with underlying risk factors, requiring the nephrology community to be familiar with the nephrotoxic effects. The most common clinical nephrotoxic manifestations of these drugs include acute kidney injury, varying levels of proteinuria, hypertension, electrolyte disturbances, and at times chronic kidney disease. Thus, to practice competently in the 'onco-nephrology' arena, nephrologists will garner benefit from an update on older drugs with newly recognized nephrotoxic potential as well as newer agents, which may be associated with kidney injury. With that in mind, this brief update is meant to provide clinicians with the currently available evidence on the nephrotoxicity of a group of anticancer medications.

Publication types

  • Review

MeSH terms

  • Adenine Nucleotides / adverse effects
  • Androgen Antagonists / adverse effects
  • Angiogenesis Inhibitors / adverse effects
  • Antibodies, Monoclonal / adverse effects
  • Antineoplastic Agents / adverse effects*
  • Arabinonucleosides / adverse effects
  • Clofarabine
  • Crizotinib
  • Humans
  • Ipilimumab
  • Kidney Diseases / chemically induced*
  • Oligopeptides / adverse effects
  • Pemetrexed / adverse effects
  • Pyrazoles / adverse effects
  • Pyridines / adverse effects


  • Adenine Nucleotides
  • Androgen Antagonists
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Arabinonucleosides
  • Ipilimumab
  • Oligopeptides
  • Pyrazoles
  • Pyridines
  • Pemetrexed
  • Crizotinib
  • carfilzomib
  • Clofarabine